Table 3.
Gene expression and biomarkers according to time to clinical stability and length of stay.
| Time to Clinical Stability | Length of Stay | |||||
|---|---|---|---|---|---|---|
| ≤3 Days | >3 Days | p-Value | ≤6 Days | >6 Days | p-Value | |
| HLA-DRA (copies/ng RNA) | 1448 (560–2412) | 924 (448–1944) | 0.142 | 1376 (560–2360) | 920 (448–1952) | 0.188 |
| ICOS (copies/ng RNA) | 15 (7–27) | 11 (5–19) | 0.087 | 12 (8–25) | 11 (5–19) | 0.180 |
| CD40LG (copies/ng RNA) | 30 (19–59) | 17 (8–28) | * 0.001 | 29 (16–57) | 19 (8–28) | * 0.008 |
| CD3E (copies/ng RNA) | 270 (185–432) | 202 (100–311) | * 0.040 | 270 (185–373) | 199 (99–368) | 0.105 |
| CD28 (copies/ng RNA) | 34 (21–65) | 24 (12–37) | * 0.011 | 31 (21–58) | 24 (17–43) | * 0.048 |
| ProET1 (pmol/L) | 69 (47–101) | 89 (62–129) | * 0.027 | 72 (48–94) | 85 (55–137) | * 0.048 |
| ProADM (nmol/L) | 0.76 (0.61–0.95) | 1 (0.75–1.45) | * 0.018 | 0.77 (0.61–1.08) | 0.9 (0.7–1.23) | 0.163 |
Data presented as median (interquartile range). For the analysis, only surviving patients at 30 days were considered. ProET1: proendothelin-1; ProADM: proadrenomedullin; HLA-DRA: histocompatibility complex class II DR alpha; ICOS: Inducible T-cell costimulator; CD40LG: CD40 ligand * p < 0.05.